Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.

Antimicrobial Agents and Chemotherapy
F H NoormohamedA F Lant

Abstract

The pharmacokinetics, absolute bioavailability, accumulation, and tolerability over 8 days of an oral formulation of foscarnet (90 mg/kg of body weight once daily [QD] [n = 6], 90 mg/kg twice daily [BID] [n = 6], and 180 mg/kg QD [n = 31) were investigated in 15 asymptomatic, human immunodeficiency virus-seropositive male patients free of active cytomegalovirus infection and with normal upper gastrointestinal function. Peak plasma drug concentrations were (mean +/- standard deviation) 46.4 +/- 10.8 microM (90 mg/kg QD), 45.7 +/- 6.9 microM (90 mg/ kg BID), and 64.9 +/- 31.7 microM (180 mg/kg QD) on day 1 and rose to 86.2 +/- 35.8, 78.7 +/- 35.2, and 86.4 +/- 25.0 microM, respectively, on day 8. The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887.3 +/- 102.7 microM (n = 13). The terminal half-life in plasma remained unchanged, averaging 5.5 +/- 2.2 h on day 1 (n = 15) and 6.6 +/- 1.9 h on day 8 (n = 13), whereas it was 5.7 +/- 0.7 h following intravenous dosing. Oral bioavailabilities were 9.1% +/- 2.2% (90 mg/kg QD), 9.5% +/- 1.7% (90 mg/kg BID), and 7.6% +/- 3.7% (180 mg/kg QD); the accumulation ratios on the 8th day of dosing were 2.1 +/- 1.1, 1.8 +/- 0.4, and 1.7 +/-...Continue Reading

References

Aug 1, 1987·Antimicrobial Agents and Chemotherapy·M A JacobsonJ Mills
Feb 1, 1985·Clinical Physiology·J Brøchner-Mortensen
Jan 1, 1982·Pharmacology & Therapeutics·B Oberg
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K C CundyH S Jaffe
Feb 1, 1993·Journal of Pharmaceutical Sciences·K K MidhaI J McGilveray
Jan 1, 1997·British Journal of Clinical Pharmacology·F H NoormohamedA F Lant

❮ Previous
Next ❯

Citations

Jul 17, 2018·Expert Review of Clinical Pharmacology·Atibordee Meesing, Raymund R Razonable
Oct 5, 2001·Expert Opinion on Pharmacotherapy·M D Khare, M Sharland
Dec 2, 2004·Expert Opinion on Emerging Drugs·Arun ChakrabartyStephen K Tyring
Sep 8, 2020·Platelets·Nima Abbasian, Matthew T Harper
Jul 2, 2018·Drugs·Atibordee Meesing, Raymund R Razonable
Nov 5, 2020·Scientific Reports·Latha KannanJeffrey Langland
Jun 26, 1999·Antimicrobial Agents and Chemotherapy·J Harmenberg, M Brytting
Apr 13, 2006·Journal of the American Chemical Society·Christina M YamadaMarvin H Caruthers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.